menu
    • menu

    Company profile for Disarm Therapeutics

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Disarm Therapeutics is creating breakthrough disease-modifying therapeutics to treat patients with neurological diseases by preventing axonal degeneration. Axonal degeneration is a common yet unaddressed pathology in a broad range of chronic and acute diseases of the central, ocular, and peripheral nervous systems. Our scientific founders have identified SARM1 as the central driver of axonal degeneration, which causes severe s...
    Disarm Therapeutics is creating breakthrough disease-modifying therapeutics to treat patients with neurological diseases by preventing axonal degeneration. Axonal degeneration is a common yet unaddressed pathology in a broad range of chronic and acute diseases of the central, ocular, and peripheral nervous systems. Our scientific founders have identified SARM1 as the central driver of axonal degeneration, which causes severe sensory, motor, and cognitive symptoms and disease progression.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Disarm TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1 Main Street, 11th Floor, Cambridge, MA 02142
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.disarmtx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/disarm/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/disarmtx?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Arvo

    Arvo

    Not Confirmed

    envelop Contact Supplier

    Arvo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Asha Therapeutics Receives ALS Grant & Appoints Disarm Founders
    Asha Therapeutics Receives ALS Grant & Appoints Disarm Founders

    13 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241113152837/en

    BUSINESSWIRE
    13 Nov 2024
    Share Share
    Biotech funder Lightstone raises another $375M for life sciences investing
    Biotech funder Lightstone raises another $375M for life sciences investing

    14 Sep 2021

    // BIOPHARMADIVE

    https://www.biopharmadive.com/news/lightstone-venture-capital-fund-raise-biotech/606545/

    BIOPHARMADIVE
    14 Sep 2021
    Share Share
    Lilly Announces Agreement to Acquire Disarm Therapeutics
    Lilly Announces Agreement to Acquire Disarm Therapeutics

    16 Oct 2020

    // PRESS RELEASE

    https://investor.lilly.com/news-releases/news-release-details/lilly-announces-agreement-acquire-disarm-therapeutics

    PRESS RELEASE
    16 Oct 2020
    Share Share
    Eli Lilly bags an early-stage biotech for the neuro team — paying $135M
    Eli Lilly bags an early-stage biotech for the neuro team — paying $135M

    15 Oct 2020

    // John Carroll ENDPTS

    https://endpts.com/eli-lilly-bags-an-early-stage-biotech-for-the-neuro-team-paying-135m-cash-and-offering-1b-plus-in-milestones/

    John Carroll ENDPTS
    15 Oct 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search